Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs

被引：74
|
作者：
Cummings, J. [1 ]
Raynaud, F. [2 ]
Jones, L. [3 ]
Sugar, R. [4 ]
Dive, C. [1 ]
机构：
[1] Univ Manchester, Paterson Inst Canc Res, Manchester M20 4BX, Lancs, England
[2] Inst Canc Res, Canc Res UK Ctr Canc Therapeut, Haddow Labs, Sutton SM2 5NG, Surrey, England
[3] Canc Res UK, Translat Res Team, Clin & Translat Operat & Funding Directorate, London WC2A 3PX, England
[4] Canc Res UK, Drug Dev Off, Clin & Translat Operat & Funding Directorate, London WC2A 3PX, England
来源：
BRITISH JOURNAL OF CANCER | 2010年 / 103卷 / 09期
关键词：
biomarkers; validation; clinical trials; fit-for-purpose; BIOANALYTICAL METHOD VALIDATION; LIGAND-BINDING ASSAYS; CELL-DEATH; CANCER; MACROMOLECULES; STABILITY; QUALITY; SAMPLES;
D O I：
10.1038/sj.bjc.6605910
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Clinical development of new anticancer drugs can be compromised by a lack of qualified biomarkers. An indispensable component to successful biomarker qualification is assay validation, which is also a regulatory requirement. In order to foster flexible yet rigorous biomarker method validation, the fit-for-purpose approach has recently been developed. This minireview focuses on many of the basic issues surrounding validation of biomarker assays utilised in clinical trials. It also provides an overview on strategies to validate each of the five categories that define the majority of biomarker assays. British Journal of Cancer (2010) 103, 1313-1317. doi: 10.1038/sj.bjc.6605910 www.bjcancer.com Published online 5 October 2010 (C) 2010 Cancer Research UK
引用
收藏
页码：1313 / 1317
页数：5
相关论文
共 50 条
  • [21] Measuring soluble biomarkers in clinical trials: do tiered approaches to the analysis and validation of assays provide an answer to the fit-for-purpose challenge?
    Hucker, Richard
    Watson, Carl
    James, Ian
    Vincent, Scott
    Muirhead, David
    BIOANALYSIS, 2014, 6 (05) : 605 - 609
  • [22] Fit-for-Purpose Biometric Monitoring Technologies: Leveraging the Laboratory Biomarker Experience
    Godfrey, Alan
    Vandendriessche, Benjamin
    Bakker, Jessie P.
    Fitzer-Attas, Cheryl
    Gujar, Ninad
    Hobbs, Matthew
    Liu, Qi
    Northcott, Carrie A.
    Parks, Virginia
    Wood, William A.
    Zipunnikov, Vadim
    Wagner, John A.
    Izmailova, Elena S.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (01): : 62 - 74
  • [23] A fit-for-purpose validation of a commercial radioimmunoassay for measurement of human peripheral oxytocin
    Gerred, Keenan
    Kapoor, Amita
    BIOCHEMISTRY AND BIOPHYSICS REPORTS, 2024, 38
  • [24] "Fit-for-purpose" PIK3CA assays for patient stratification in breast cancer clinical trials
    Gong, Hua C.
    Manjeshwar, Sharmila
    Abraham, Violet
    Rivera, Shawn
    CANCER RESEARCH, 2019, 79 (13)
  • [25] Fit-for-purpose curated database application in mass spectrometry-based targeted protein identification and validation
    Cheng K.
    Sloan A.
    McCorrister S.
    Babiuk S.
    Bowden T.R.
    Wang G.
    Knox J.D.
    BMC Research Notes, 7 (1)
  • [26] Fit-for-purpose bioanalytical cross-validation for LC-MS/MS assays in clinical studies
    Xu, Xiaohui
    Ji, Qin C.
    Jemal, Mohammed
    Gleason, Carol
    Shen, Jim X.
    Stouffer, Bruce
    Arnold, Mark E.
    BIOANALYSIS, 2013, 5 (01) : 83 - 90
  • [27] A fast and fit-for-purpose arsenic speciation method for wine and rice
    Gray, Patrick J.
    Tanabe, Courtney K.
    Ebeler, Susan E.
    Nelson, Jenny
    JOURNAL OF ANALYTICAL ATOMIC SPECTROMETRY, 2017, 32 (05) : 1031 - 1034
  • [28] Application of the International System of Radiation Protection in Fit-for-Purpose Assessment of Impacts
    Yankovich, Tamara L.
    BIOMARKERS OF RADIATION IN THE ENVIRONMENT: ROBUST TOOLS FOR RISK ASSESSMENT, 2022, : 285 - 302
  • [29] Making sense of sensors: selecting, incorporating, and analyzing fit-for-purpose technologies for continuous data capture in clinical trials
    不详
    QUALITY OF LIFE RESEARCH, 2020, 29 (SUPPL 1) : S17 - S17
  • [30] Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for Biometric Monitoring Technologies (BioMeTs)
    Jennifer C. Goldsack
    Andrea Coravos
    Jessie P. Bakker
    Brinnae Bent
    Ariel V. Dowling
    Cheryl Fitzer-Attas
    Alan Godfrey
    Job G. Godino
    Ninad Gujar
    Elena Izmailova
    Christine Manta
    Barry Peterson
    Benjamin Vandendriessche
    William A. Wood
    Ke Will Wang
    Jessilyn Dunn
    npj Digital Medicine, 3
12345